STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts
Missouri AG told Lilly to stop forcing hospitals to provide claims data to receive discounted medicines under 340B, a sign more states are pushing back against drugmakers.
Missouri Attorney General Catherine Hanaway has issued a cease-and-desist letter to pharmaceutical giant Eli Lilly, urging the company to cease requiring hospitals seeking 340B drug discounts to provide claims data, indicating a growing trend of states challenging such practices by drug manufacturers. The letter, sent on October 26th, alleged that Lilly has breached its commitment to provide its medications under the 340B Drug Pricing Program to eligible hospitals in the state.
Hanaway contended that the drugmaker had made "false and misleading statements" and violated state law. She cited University of Missouri Health Care, which operates seven hospitals in the state and reportedly agreed to provide claims data, yet allegedly denied the hospital discounts on its medications despite the arrangement. Hanaway has given Lilly until November 26th to halt its new policy. For the complete story, continue to STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
